Clinical trials: Leishmaniasis, active
Leishmaniasis, Visceral
Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)
According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.
- Trial name
- NCT06793111
- Where
- 5 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
The goal of this clinical trial is to learn if the drug MILTEFOSINE, used topically in a hydrogel, works to treat non-complicated cutaneous leishmaniasis (CL) in adults.
- Conditions
- Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American, Topical Administration
- Trial name
- G-MTF01 (NCT07149753)
- Testing
- MILTEFOSINE gel
- Where
- Colombia
- Volunteers
- 15 people
- Sponsor
- Universidad Industrial de Santander
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Cutaneous Leishminiasis
Comparison of Intralesional Glucantime With and Without Fractional CO₂ Laser in Adults With Cutaneous Leishmaniasis
Cutaneous leishmaniasis is a common parasitic skin disease causing chronic ulcerative lesions and scarring. Intralesional meglumine antimoniate (Glucantime) is a widely used treatment; however, healing may be prolonged and…
- Trial name
- NCT07652021
- Testing
- Meglumine Antimoniate, Fractional CO₂ laser
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Combined military hospital Peshawar
Cutaneous Leishmaniasis, Pain
Immersive Technology Headsets to Reduce Procedural Pain and Anxiety: Feasibility and Effects in Cutaneous Leishmaniasis Patients in Pakistan
The goal of this clinical trial is to learn whether immersive technology (virtual reality) headsets can reduce procedural pain and anxiety during diagnosis, intralesional and intramuscular injections, and wound/dressing care in…
- Conditions
- Cutaneous Leishmaniasis, Pain, Anxiety
- Trial name
- NCT07858357
- Testing
- Virtual Reality
- Volunteers
- 15 people
- Sponsor
- Stanford University
Cutaneous Leishmaniasis
Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care Setup
This study will look at how feasible it is to use thermotherapy (TT) as a treatment for skin(cutaneous) leishmaniasis (CL) in health centers in the Sodo and South Sodo districts, Ethiopia.
- Trial name
- TTCL (NCT06746350)
- Testing
- Thermotherapy
- Where
- Ethiopia
- Volunteers
- 103 people
- Sponsor
- Armauer Hansen Research Institute, Ethiopia
Leishmaniasis, Cutaneous
Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia
This clinical trial aims to evaluate the effectiveness of combining the standard treatment for complicated cutaneous leishmaniasis (CL), sodium stibogluconate (SSG), with either topical fusidic acid 2% cream or a vehicle cream…
- Trial name
- AIM-CL (NCT06695143)
- Testing
- Fusidic Acid, Vehicle cream
- Where
- 2 sites in Ethiopia
- Volunteers
- 180 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Leishmaniasis
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
L. infantum leishmaniasis is endemic in the South of France. For several years, there has been an expansion of the territory of sandflies (vector of leishmaniasis), with the appearance of cases of canine leishmaniasis in new…
- Trial name
- AsymptoGen (NCT03784248)
- Testing
- blood donation and isolation of leuco-platelet layers
- Where
- France
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Kinetoplastid, Skin Diseases, Parasitic
Diagnosis and Treatment of Leishmania Infections
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural…
- Conditions
- Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis
- Trial name
- NCT00344188
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leishmaniasis, Cutaneous
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis (CL) is a parasitic disease caused by more than 20 different species of the protozoan parasite Leishmania.
- Trial name
- ARNICA (NCT05094908)
- Testing
- Arnica Tincture
- Where
- Colombia
- Volunteers
- 16 people
- Sponsor
- Universidad de Antioquia
Cutaneous Leishmaniasis
Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis
Aim of the study to evaluate the effectiveness of intralesional levofloxacin 0.5% solution as a local injection in treating cutaneous leishmaniasis.
- Trial name
- NCT06797544
- Testing
- Levofloxacin 0.5%
- Where
- Iraq
- Volunteers
- 40 people
- Sponsor
- Hayder Adnan Fawzi
Leishmaniasis
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
This is an exploratory experimental multicentre study on archived serum samples and on prospectively collected serum samples and blood samples.
- Trial name
- LeishmARPs (NCT06307171)
- Testing
- In-house Western blot, specific for Leishmania
- Where
- Italy
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Visceral Leishmaniasis
Clinical Prognostic Score to Predict Relapse in VL
This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia.
- Trial name
- CPS (NCT05602610)
- Testing
- No intervention
- Where
- Ethiopia
- Volunteers
- 741 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Hiv, Visceral Leishmaniasis
Recurrent Visceral Leishmaniasis in HIV Co-Infection
The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target…
- Trial name
- ALIVE (NCT07487350)
- Where
- Ethiopia
- Volunteers
- 20 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis
Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis
Aim of the study to evaluate the effectiveness of intralesional metronidazole 0.5% solution as a local injection in treating cutaneous leishmaniasis.
- Trial name
- NCT06798415
- Testing
- Metronidazole
- Where
- Iraq
- Volunteers
- 40 people
- Sponsor
- Hayder Adnan Fawzi
Visceral Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
ImmStat@Cure is a multicentre observational study designed to assess the immune status of patients before and after treatment for visceral leishmaniasis. Forty patients and 30 controls will be recruited per site.
- Trial name
- NCT04342715
- Testing
- Sodium stibogluconate / paramomycin
- Where
- Kenya
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of York
Cutaneous Leishmaniasis
Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate
The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and compare its effect with intralesional sodium stibogluconate (SSG) 10%…
- Trial name
- NCT06798402
- Testing
- Ciprofloxacin (BAYO9867), sodium stibogluconate (Pentostam)
- Where
- Iraq
- Volunteers
- 80 people
- Sponsor
- Al-Mustafa University College
Leishmaniasis, Cutaneous, Leishmaniasis
Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis
This study assesses the immunoprevalence (presence of the induced T-cell response across different patients (and thus HLA types) of six prioritized IPX-derived Leishmania antigens, using Good Laboratory Practice-grade soluble…
- Conditions
- Leishmaniasis, Cutaneous, Leishmaniasis, Leishmaniasis, Visceral, Immunogenicity
- Trial name
- LEISHVAC (NCT07783243)
- Where
- 2 sites in Ethiopia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniases
OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
While there are indications that 28 days of miltefosine is not sufficient for treating CL by L. aethiopica, a better understanding of what happens in terms of parasite clearance and drug dosing is lacking.
- Trial name
- OPTIMILEISH (NCT06514560)
- Testing
- Miltefosine
- Where
- Ethiopia
- Volunteers
- 80 people
- Sponsor
- Institute of Tropical Medicine, Belgium